3 New Strong Buy Ratings from Top-Rated Analysts: 11/03/2026
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Pharming Group (PHAR): Two top analysts see the stock roughly tripling
- Nucor Corporation (NUE): Strongest steel demand in 31 years, says CEO
- Regeneron Pharmaceuticals (REGN): Top-rated biotech with Dupixent and Eylea surging
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
Nucor Corporation (NYSE: NUE)
This giant industrial company is benefiting from what its CEO describes as the strongest steel demand in 30+ years, driven by AI infrastructure buildout and new tariff tailwinds, setting up a robust growth trajectory into 2027.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $273.87 — get current quote
Max 1-year forecast: $320.00
Why we're watching:
- NUE has strong, bullish coverage among the analysts we track, with 7 Strong Buy, 1 Buy, and 2 Hold recommendations. See all recommendations here
- For example, Wells Fargo researcher Timna Tanners (a top 12% rated analyst) recently maintained a Strong Buy recommendation, as did BMO Capital researcher Katja Jancic (a top 10% rated analyst) … Both of whom forecast ample upside from current levels.
- Industry ranking context: NUE is currently the #2 highest-rated stock in the Steel industry, which has an Industry Rating of A.
- Zen Ratings highlights: NUE earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: NUE demonstrates strong Bs for Financials, Growth, Momentum, and Safety, reflecting the company's solid balance sheet and favorable positioning for the infrastructure and AI data center boom ahead. See all 7 Component Grades here
2. Regeneron Pharmaceuticals (NASDAQ: REGN)
This global biopharmaceutical enterprise is riding strong momentum following exceptional Q3 results, with blockbuster drugs Dupixent and Eylea HD driving impressive growth and profitability.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $927.89 — get current quote
Max 1-year forecast: $1,050.00
Why we're watching:
- REGN has broad, bullish coverage among the analysts we track, with 13 Strong Buy, 1 Buy, and 6 Hold recommendations. See all recommendations here
- For example, JP Morgan researcher Chris Schott (a top 10% rated analyst) recently maintained a Strong Buy recommendation; UBS researcher Trung Huynh (a top 10% rated analyst) just upgraded REGN to Strong Buy. They both see significant upside from current levels.
- Industry ranking context: REGN is currently the #1 highest-rated stock in the Biotech industry, which has an Industry Rating of F.
- Zen Ratings highlights: REGN receives an overall A rating, which is equal to a Strong Buy recommendation. This designation identifies the company as among the elite top 5% based on a comprehensive 115-factor fundamental evaluation.
- Component Grades: REGN excels with an A for Sentiment and strong Bs for Financials, Growth, Safety, and Value, underscoring both the market's enthusiasm for its pipeline and the company's strong execution and profitability. See all 7 Component Grades here
3. Pharming Group (NASDAQ: PHAR)
Protein replacement therapies and precision medicines are the name of the game for this pharma company. If that doesn’t mean anything to you, how about this part: The company is gaining momentum with strong Q3 results and positive Phase II data on one of its products, and analysts believe it could surge over 200% in the coming year.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $12.23 — get current quote
Max 1-year forecast: $41.00
Why we're watching:
- PHAR has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy and 1 Buy recommendations. See all recommendations here
- For example, HC Wainwright & Co. researcher Joseph Pantginis (a top 6% rated analyst) reiterated a Buy with a price target suggesting the stock could see 200% upside potential from current levels.
- Better still, Canaccord Genuity researcher Whitney Ijem (a top 8% rated analyst) recently maintained a Strong Buy with a price target representing 235% upside potential from current levels.
- Industry ranking context: PHAR is currently the #8 highest-rated stock in the Biotech industry … but remember, biotechs are speculative, as reflected by the Industry Rating of F.
- Zen Ratings highlights: PHAR earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all stocks tracked based on a rigorous 115-factor fundamental review.
- Component Grades: PHAR demonstrates balance with solid Bs for Growth and Value, suggesting the company's pipeline and commercial execution are being recognized by the market despite the challenging biotech sector backdrop. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.